What Evidence is Essential for New Medical Products?
Implications for Patients and Health Policy
June 13, 2014
12th and H streets NW
This event is co-sponsored by the American Association for the Advancement of Science, the Division of Pharmacoepidemiology and Pharmacoeconomics of Brigham and Women’s Hospital/Harvard Medical School, and the National Center for Health Research.
Better implementation of evidence-based medicine can improve the quality and cost-effectiveness of health care in the U.S. This can be challenging in evaluating newly approved drugs and medical devices. While current law requires that medical products be proven safe and effective, there is growing pressure to expedite access to promising therapies and to lessen the research and regulatory requirements for manufacturers. Unmet medical needs and patient demands call for a flexible approach to prescription drug and device regulation, but truncated premarket review may also lead to approval of products that are less effective than expected or have unanticipated safety problems. This groundbreaking conference will review the growing body of research on the medical and public health implications of medical product approval criteria, and examine these findings in the context of patient outcomes, costs, and health policy.
There is no cost for attending the event, but space is limited and advance registration is required.
The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science as well as Science Translational Medicine and Science Signaling. AAAS was founded in 1848 and includes some 262 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million. The non-profit AAAS is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy; international programs; science education; and more. For the latest research news, log onto EurekAlert! the premier science-news website, a service of AAAS. www.aaas.org.
About the Division of Pharmacoepidemiology and Pharmacoeconomics of Brigham and Women's Hospital/Harvard Medical School
The Division of Pharmacoepidemiology and Pharmacoeconomics—which is part of the Department of Medicine at Brigham and Women’s Hospital (BWH), a teaching hospital of Harvard Medical School—facilitates a wide range of activities related to the use and outcomes of medications, addressed from a variety of interdisciplinary perspectives. Its mission is to bring together the various specialties of medicine, epidemiology, biostatistics, health services research, and the social sciences to evaluate the effectiveness of existing and new prescription drugs in relation to their risks and costs; to study how medications are used by physicians and patients; and to develop methods to optimize prescription drug use. Within the Division, the Program On Regulation, Therapeutics, And Law (PORTAL) engages in research and training that considers how laws and regulations influence the development, utilization, and affordability of therapeutics, as well as the ethical questions these issues raise for patients, physicians, policymakers, and payors. http://www.drugepi.org/portal/.
About the National Center for Health Research
The National Center for Health Research uses scientific evidence to promote the health of men, women, and children through more effective programs and policies. The Center achieves its mission by conducting research, analyzing and scrutinizing information, and explaining the implications of the findings for patients and public health. The Center provides information for free to the public, the media, opinion leaders, and policy makers. In addition to helping individuals, the Center works on the local, state, and national level to inform policies with implications for human health. Center staff testify before the U.S. Congress; federal agencies such as the Food and Drug Administration, the Centers for Disease Control and Prevention, and the Environmental Protection Agency; and state legislators about the strength and weaknesses of programs and policies, and about the comparative safety and effectiveness of medicines and other products in our homes and communities. center4research.org.
Copyright © 2014. American Association for the Advancement of Science.